COVID-19 oral treatment listed on PBS from 1 May 2022
From 1 May 2022, Paxlovid will be available through the Pharmaceutical Benefits Scheme (PBS) for Australians at high risk of developing severe COVID-19.
This prescription-only oral treatment has been found to be effective in treating mild to moderate COVID-19 in adults aged 18 years of age and older, who do not require supplemental oxygen, and who are at increased risk of progressing to hospitalisation.
For more information about oral treatments for COVID-19, including Paxlovid.
Find out more about Paxlovid.
Download the PBS fact sheet
PBAC Web Outcome Statement: NIRMATRELVIR AND RITONAVIR (Paxlovid)
Consumer resources for Paxlovid on NPS MedicineWise